BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12767363)

  • 1. Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort.
    Aus G; Nordenskjöld K; Robinson D; Rosell J; Varenhorst E
    Eur Urol; 2003 Jun; 43(6):627-31. PubMed ID: 12767363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen for prostate cancer staging in a population-based register.
    Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
    Scand J Urol Nephrol; 2002; 36(2):99-105. PubMed ID: 12028682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
    Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
    Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of prostate carcinoma death in patients with lymph node metastasis.
    Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
    Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
    Stock RG; Stone NN; Ianuzzi C; Unger P
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
    Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
    Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
    Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
    Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
    Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 1989 patterns of care study for prostate cancer: five-year outcomes.
    Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
    Perez CA; Michalski J; Brown KC; Lockett MA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
    Arenas LF; Füllhase C; Boemans P; Fichtner J
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting pelvic lymph node involvement in patients with localized prostate cancer.
    Ekman P
    Eur Urol; 1997; 32 Suppl 3():60-4. PubMed ID: 9267787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we reconsider the indications for ileo-obturator node dissection with localized prostate cancer?
    Sullivan LD; Rabbani F
    Br J Urol; 1995 Jan; 75(1):33-7. PubMed ID: 7531590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.